Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Oncol
Asıl Yazarlar: Dimopoulos, Konstantinos, Søgaard Helbo, Alexandra, Fibiger Munch‐Petersen, Helga, Sjö, Lene, Christensen, Jesper, Sommer Kristensen, Lasse, Asmar, Fazila, Hermansen, Niels Emil Ulrich, O'Connel, Casey, Gimsing, Peter, Liang, Gangning, Grønbæk, Kirsten
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792743/
https://ncbi.nlm.nih.gov/pubmed/29130642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12157
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller